Blair William & Co. IL Takes $81,000 Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Blair William & Co. IL bought a new position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) during the fourth quarter, Holdings Channel.com reports. The fund bought 12,000 shares of the company’s stock, valued at approximately $81,000.

A number of other large investors have also recently made changes to their positions in RXRX. Vanguard Group Inc. grew its holdings in Recursion Pharmaceuticals by 40.1% during the 4th quarter. Vanguard Group Inc. now owns 34,009,994 shares of the company’s stock worth $229,908,000 after acquiring an additional 9,737,196 shares in the last quarter. State Street Corp increased its holdings in Recursion Pharmaceuticals by 47.1% in the third quarter. State Street Corp now owns 12,870,272 shares of the company’s stock valued at $84,815,000 after buying an additional 4,120,685 shares during the last quarter. Geode Capital Management LLC increased its holdings in Recursion Pharmaceuticals by 13.7% in the third quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company’s stock valued at $35,803,000 after buying an additional 656,003 shares during the last quarter. Institute for Wealth Management LLC. purchased a new stake in Recursion Pharmaceuticals during the 4th quarter worth about $3,928,000. Finally, Platinum Investment Management Ltd. boosted its position in shares of Recursion Pharmaceuticals by 293.9% during the 4th quarter. Platinum Investment Management Ltd. now owns 733,011 shares of the company’s stock worth $4,955,000 after acquiring an additional 546,929 shares in the last quarter. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

RXRX has been the subject of several recent analyst reports. KeyCorp decreased their target price on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th. Needham & Company LLC restated a “buy” rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research report on Thursday, February 6th. Leerink Partners dropped their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating on the stock in a research report on Friday, February 28th. Finally, Cowen reiterated a “hold” rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $8.25.

Recursion Pharmaceuticals Price Performance

Shares of RXRX opened at $4.24 on Monday. The company has a market capitalization of $1.70 billion, a price-to-earnings ratio of -2.77 and a beta of 1.00. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $4.06 and a fifty-two week high of $12.36. The firm has a 50-day simple moving average of $7.22 and a 200-day simple moving average of $6.95. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings data on Friday, February 28th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.17). The firm had revenue of $4.60 million for the quarter, compared to analysts’ expectations of $19.04 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The firm’s quarterly revenue was down 57.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.42) EPS. On average, equities research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.